Abeona Therapeutics reports Q2 EPS (14c), consensus (17c) » 16:2508/1008/10/20
Cash, cash equivalents…
Cash, cash equivalents and short-term investments totaled $107.9 million as of June 30, 2020, compared to $129.3 million as of December 31, 2019. Net cash used in operating activities was $9.5 million for the second quarter 2020. "During the past several months, Abeona has delivered on our goals in clinical development, manufacturing, and regulatory affairs toward bringing urgently needed treatments to patients with RDEB and MPS III," said Joao Siffert, M.D., Chief Executive Officer of Abeona. "Notably, new patients have been treated in our RDEB and MPS IIIA clinical programs, and we expect additional patient enrollment across our clinical programs in the coming weeks. Concurrent with the increased clinical activities, we resumed internal manufacturing operations at our Cleveland campus in June. We have made significant advancements in process development for retrovirus and AAV manufacturing in-house, anticipated to start in late-2020 and early-2021, respectively. In addition, we recently reached general alignment with the CHMP on our proposed path toward a European marketing authorization application for ABO-102 in MPS IIIA, anticipated in 2023. Looking ahead to the potential commercial launches of EB-101 in late-2022 and ABO-102 the following year, we have also strengthened our leadership team, bringing on board a Chief Commercial Officer with significant relevant experience and expertise."
Google reports filing supplemental brief in legal case with Oracle » 13:3808/0708/07/20
GOOG, GOOGL, ORCL
Kent Walker, SVP of…
Kent Walker, SVP of Global Affairs, posted to the Google blog, stating in part: "Open software interfaces have been an integral part of the innovation economy. They enable the interoperability that has always let software developers build on each other's work. And the interoperability of open software interfaces is what lets different technologies like apps work together on a variety of devices and platforms: That's why you can take a photo on an Apple phone, save it onto Google's cloud servers, and edit it on a Surface tablet. Our legal case with Oracle turns on our belief that interoperability has been good for innovation, good for developers, and good for consumers... Today, we filed a supplemental brief explaining how the jury in our case heard from over a dozen witnesses, reviewed hundreds of documents, and then unanimously agreed with our position. America's Constitution enshrines the right to a jury trial. The Supreme Court has recognized the important role of a jury in deciding nuanced, fact-specific questions like the ones in this case. A decision in Oracle's favor would limit consumers' freedom to use technologies on a range of devices. It would upend the way developers have always used software interfaces, locking them into existing platforms and giving copyright owners new power to control the building blocks of new technologies. And it would erode the traditional role of the jury in evaluating all the facts relevant to a decision. We look forward to making this case to the Court on October 7." Reference Link
|Over a week ago|
Gladstone Land reports Q2 EPS 10c versus 5c in prior quarter » 16:3908/0508/05/20
Reports Q2 revenue…
Reports Q2 revenue $12.6M, consensus $12.69M.Net income for the quarter was approximately $182,000, compared to approximately $3.1 million in the prior quarter. Net loss to common stockholders and non-controlling OP Unitholders during the quarter was approximately $2.1 million, or $0.10 per share, compared to net income to common stockholders and non-controlling OP Unitholders of approximately $976,000, or $0.05 per share, in the prior quarter. Reports Q2 FFO 10.9c
Oracle to partner with NIH on cloud system to support COVID-19 vaccine trials » 16:3207/1607/16/20
The National Institute of…
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, recently established the COVID-19 Prevention Network. Its goal is to register millions of volunteers for large-scale clinical testing of vaccines and monoclonal antibodies intended to protect people from COVID-19. As part of this initiative, Oracle developed a Cloud System called the CoVPN Volunteer Screening Registry to identify and screen volunteers who want to participate in COVID-19 clinical trials. Even though the system has been live for less than a week, more than 100,000 people have already registered. This program is expected to support hundreds of clinical trial sites across the United States and internationally by the end of the year.
Google accused of tracking user activity even after opting out, Reuters reports » 06:0007/1507/15/20
GOOG, GOOGL, FB, ORCL
A lawsuit filed Tuesday…
A lawsuit filed Tuesday alleges Google (GOOGL) tracks user activity through hundreds of thousands of apps, even after people opt out of sharing information, Reuters' Paresh Dave reports. Boies Schiller Flexner has represented competitors to Google, including Facebook (FB) and Oracle (ORCL), according to the report. The complaint accuses Google of violating federal wiretap law and California privacy law by logging what users are looking at in news, ride-hailing and other types of apps despite them having turned off "Web & App Activity" tracking in their Google account settings. Reference Link
Rimini Street appoints Gerard Brossard as COO » 09:1307/1307/13/20
RMNI, ORCL, SAP
Rimini Street (RMNI)…
Rimini Street (RMNI) announced the appointment of Gerard Brossard to the newly created role of executive vice president and COO. Brossard is responsible for Rimini Street's global field operations and the global sales and success of the company's support and application management services for Oracle (ORCL) and SAP (SAP) products. Brossard reports directly to Rimini Street CEO, Seth Ravin. Prior to joining Rimini Street, Brossard served as executive vice president and general manager of Rackspace's global solutions and services group, where he had P&L responsibility for all products, solutions and services.
|Over a month ago|
Society for Pediatric Dermatology to hold virtual meeting » 05:5507/1207/12/20
ABEO, AMGN, DRMT, NVS, PFE, SNY, VRCA
Society for Pediatric Dermatology to hold virtual meeting » 04:5507/1107/11/20
ABEO, AMGN, DRMT, NVS, PFE, SNY, VRCA
Society for Pediatric Dermatology to hold virtual meeting » 10:1807/1007/10/20
ABEO, AMGN, DRMT, NVS, PFE, SNY, VRCA
Abeona Therapeutics announces two presentations related to RDEB program » 07:3407/1007/10/20
Abeona Therapeutics announced that two poster presentations related to its clinical program for recessive dystrophic epidermolysis bullosa, or RDEB, were featured at the Society for Pediatric Dermatology, or SPD, 45th annual meeting. The first poster includes a detailed analysis of patients with RDEB in the EB-101 Phase 1/2a trial showing that wound healing following EB-101 treatment was associated with improved long-term pain relief. A separate poster provides insights on the significant disease burden associated with RDEB, highlighting data from a literature review on the clinical characteristics, humanistic consequences and economic impact of living with RDEB on patients and their families. The company alsopresented findings from a literature review of 65 studies that provide new insights on the disease burden from the perspective of patients with RDEB and their families. Key observations of the clinical, humanistic and economic burden of RDEB include: Large, chronic wounds comprise a major clinical burden of RDEB and are correlated with pain.Many patients experience anxiety and depression. Parents of children with RDEB reported negative effects on their relationship, choosing to not have more children. 50% of U.S. families characterized the economic impact of managing RDEB as "high" or "severe."